Clinical Trials · NCT00439751
Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
- Enrollment
- 79
- Start date
- Apr 2007
- Locations
- 11 sites, Canada
- Primary endpoint
- Time to androgen independent disease (AID). AID is defined as the time from randomization to AID or last follow-up.